Untitled Document
www.expresspharmaonline.com FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS
1-15 May 2006  
Untitled Document
Sections

Market
Management
 Research
Pharma Life

Services
Open Forum
Subscribe/Renew
Archives
Contact Us
Events
Pharma Excellence Awards
Network Sites
Express Computer
Network Magazine India
Express Hospitality
Express TravelWorld
feBusiness Traveller
Exp. Healthcare Mgmt.
Express Textile
Group Sites
ExpressIndia
Indian Express
Financial Express

Partner Assns.
Home - Market - Article

Company Watch

Zydus Cadila receives tentative approval for Levofloxacin

Our News Bureau - Mumbai

Zydus Cadila has received tentative approval from the USFDA to market Levofloxacin Tablets, 250 mg, 500 mg and 750 mg in the US market. The drug falls in the anti-infective segment.

The branded sales of Levofloxacin Tablets in the US market in 2005 was estimated at $1.2 billion (NDC). The company will market the drug through its US subsidiary, Zydus Pharmaceuticals (USA), following patent expiry.

This marks the thirteenth ANDA approval for the group, since the commencement of filing process in FY 2003-04. So far, the group has filed 36 ANDAs and 40 DMFs.

 


Untitled Document
Untitled Document
© Copyright 2001: Indian Express Newspapers (Mumbai) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Mumbai) Limited. Site managed by BPD.